Tag: biotechnology
-
Biosimilars Developer Lands $85 Million in IPO
7 November 2014. Coherus BioSciences Inc., a company developing medications comparable to brand-name biologic therapies, raised $85 million yesterday in its initial public stock offering. The Redwood City, California company trades on the NASDAQ exchange under the symbol CHRS. Coherus valued its 6,296,300 initial shares at $13.50. The stock opened today at $12.74 a share,…
-
Patent Awarded for Replacement Pancreas Cell Processes
6 November 2014. ViaCyte Inc., a biotechnology company in San Diego, received a patent for its processes in making early stage pancreatic cells to replace defective cells in patients with type 1 diabetes. Patent number 8,859,286 was awarded in mid-October by U.S. Patent and Trademark Office to inventor Alan Agulnick, a researcher at ViaCyte, and…
-
Patent Issued for Engineered Peptides Forming Hydrogels
4 November 2014. Bioengineers at Kansas State University received a patent for their invention of a peptide, a protein-like compound, that turns into water-based gels for a number of medical applications. U.S. Patent and Trademark Office awarded patent number 8,835,395 to Xiuzhi (Susan) Sun, professor of grain science and bioengineering at Kansas State, as well…
-
Natural Product Can Boost Animal Immune Health
31 October 2014. Tests by Avivagen Inc. show an ability of beta-carotene to spontaneously oxidize that offers a natural alternative to antibiotics added to livestock feed to reduce illness and gain weight. The researchers from Avivagen, an animal health products company in Ottawa, Canada and National Research Council of Canada published their findings in today’s…
-
Paper-Based Synthetic Bio Sensors, Circuits Developed
24 October 2014. Biomedical engineers at Harvard University designed systems with simple sensors applied on paper to detect complex cellular reactions that can speed use of point-of-care diagnostics in the field. Findings from the team at Harvard’s Wyss Institute for Biologically Inspired Engineering, with colleagues from Boston University and Howard Hughes Medical Institute in Chevy…
-
Biotech, McGill Univ Partner on Soil Enhancement Microbes
23 October 2014. Inocucor Technologies Inc. and McGill University are collaborating on development of new types of microbes that improve soil for greater yields of large-scale crops such as corn and soybeans. Financial details of the research and licensing agreement between the company and university, both in Montreal, Quebec, Canada, were not disclosed. Inocucor Technologies…
-
Project Developing DNA Antibodies for Infectious Diseases
21 October 2014. The biotechnology company Inovio Pharmaceuticals Inc. and partners are developing synthetic antibodies based on DNA that generate an immune reaction to prevent infectious diseases, a project funded by Department of Defense Advanced Research Projects Agency or DARPA. The $12.2 million DARPA grant is supporting the work of Inovia, in Plymouth Meeting, Pennsylvania,…
-
Personalized Leukemia Immunotherapy Gets 90 Pct Remission
16 October 2014. Nine in 10 children and adults in early-stage clinical trials of a personalized therapy harnessing the patients’ immune systems achieved full remission of their acute lymphoblastic leukemia. The findings of the team from University of Pennsylvania and Children’s Hospital of Philadelphia are reported today in New England Journal of Medicine (paid subscription…
-
Cancer Therapy Biotech Raises $24M in Early Funding
14 October 2014. Raze Therapeutics, a biotechnology company designing cancer therapies that stop mechanisms feeding the growth of cancer cells, raised $24 million in its first round of venture financing. The funding round was led Atlas Venture — that co-founded Raze and provided some of its seed capital — as well as MPM Capital Management,…
-
Drug Screening Target Designed for All Ebola Types
8 October 2014. Researchers at University of Utah and Navigen Inc., both in Salt Lake City, designed a synthetic peptide acting like a protein found in all strains of the Ebola virus that can serve as a target when screening for potential drugs to treat patients with the deadly disease. The team led by Utah…